Chargement...
In May 2022, with the help of our partner physicians, we presented the results of our first R-Evolution clinical study. This study aimed to demonstrate the safety and efficacy of R-One, our first solution dedicated to the optimization of coronary angioplasty via robotic assistance. It achieved its objectives with a 100% clinical success rate (no robot-related complications at 0 and 30 days), a technical success rate of over 95% and a reduction in X-ray exposure for physicians of 84.5%. For more information, download the summary brochure of the results below or watch our symposium, held at the EuroPCR2022 congress, in which the principal investigators of the study present the results.